CinRx touts positive early-stage data from two obesity candidates

Katherine Lewin

News Reporter

CinFina Pharma, a subsidiary of the hub-and-spoke biotech CinRx, shared early-stage data for two of its Janssen-licensed obesity candidates at this year’s ObesityWeek.

CIN-110, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CinRx touts positive early-stage data from two obesity candidates

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Is there room for MASH drugs in a GLP-1 world?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

The election is Tuesday. What’s at stake for the pharma industry?

BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Cin­Rx touts pos­i­tive ear­ly-stage da­ta from two obe­si­ty can­di­dates

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

CinRx touts positive early-stage data from two obesity candidates